Table of Content

"1    INTRODUCTION    29
1.1    STUDY OBJECTIVES    29
1.2    MARKET DEFINITION    29
1.2.1    INCLUSIONS AND EXCLUSIONS    30
1.3    MARKET SCOPE    31
1.3.1    MARKETS COVERED    31
FIGURE 1    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET    31
1.3.2    YEARS CONSIDERED    31
1.4    CURRENCY    32
1.5    LIMITATIONS    32
1.6    STAKEHOLDERS    32
2    RESEARCH METHODOLOGY    34
2.1    RESEARCH DATA    34
FIGURE 2    RESEARCH DESIGN    34
2.1.1    SECONDARY DATA    35
2.1.1.1    Key data from secondary sources    36
2.1.2    PRIMARY DATA    36
FIGURE 3    PRIMARY SOURCES    36
2.1.2.1    Key data from primary sources    37
2.1.2.2    Key industry insights    38
FIGURE 4    BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET)    38
FIGURE 5    BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):  BY COMPANY TYPE, DESIGNATION, AND REGION    39
2.2    MARKET SIZE ESTIMATION    39
FIGURE 6    SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS    40
FIGURE 7    REVENUE SHARE ANALYSIS ILLUSTRATION: OLYMPUS CORPORATION    40
FIGURE 8    SUPPLY-SIDE MARKET SIZE ESTIMATION: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2020)    41
FIGURE 9    CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026)    42
FIGURE 10    CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS    43
FIGURE 11    TOP-DOWN APPROACH    44
2.3    MARKET BREAKDOWN AND DATA TRIANGULATION    44
FIGURE 12    DATA TRIANGULATION METHODOLOGY    44
2.4    MARKET SHARE ESTIMATION    45
2.5    STUDY ASSUMPTIONS    45
2.6    LIMITATIONS    46
2.6.1    METHODOLOGY-RELATED LIMITATIONS    46
2.7    RISK ASSESSMENT    46
2.8    ASSESSMENT OF IMPACT OF COVID-19 ON ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET    47
3    EXECUTIVE SUMMARY    48
FIGURE 13    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2021 VS. 2026 (USD MILLION)    48
FIGURE 14    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2021 VS. 2026 (USD MILLION)    49
FIGURE 15    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY END USER, 2021 VS. 2026 (USD MILLION)    49
FIGURE 16    GEOGRAPHICAL SNAPSHOT OF THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET    50
4    PREMIUM INSIGHTS    51
4.1    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET OVERVIEW    51
FIGURE 17    INCREASING INCIDENCE OF CANCER AND THE GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES ARE THE KEY FACTORS DRIVING MARKET GROWTH    51
4.2    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET:  GEOGRAPHICAL GROWTH OPPORTUNITIES    52
FIGURE 18    CHINA TO WITNESS THE HIGHEST GROWTH IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET DURING THE FORECAST PERIOD    52
4.3    NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT AND COUNTRY (2020)    53
FIGURE 19    THE ENDOSCOPES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ERCP MARKET IN NORTH AMERICA FOR 2020    53
4.4    REGIONAL MIX: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026)    54
FIGURE 20    THE ASIA PACIFIC AND LATIN AMERICA REGIONS ARE EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026)    54
4.5    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: DEVELOPED VS. DEVELOPING MARKETS    54
FIGURE 21    DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD    54
5    MARKET OVERVIEW    55
5.1    INTRODUCTION    55
5.2    MARKET DYNAMICS    56
FIGURE 22    MARKET DYNAMICS: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET    56
5.2.1    MARKET DRIVERS    56
5.2.1.1    Rising incidence of cancer    56
FIGURE 23    GLOBAL AGE-STANDARDIZED INCIDENCE RATES OF PANCREATIC CANCER, 2020    57
5.2.1.2    Increasing investments, funds, and grants by governments and healthcare organizations to improve endoscopy research    57
TABLE 1    MAJOR DEVELOPMENTS    57
5.2.1.3    Growing focus on investments by hospitals for advanced endoscopy instruments    58
TABLE 2    SOME EXAMPLES OF INVESTMENTS BY HOSPITALS FOR ENDOSCOPY INSTRUMENTS    58
5.2.1.4    Increasing preference for minimally invasive surgeries    59
FIGURE 24    ENDOSCOPIC GLOBAL MINIMALLY INVASIVE MARKET SIZE (2019-2030)    59
5.2.2    MARKET RESTRAINTS    59
5.2.2.1    High costs of endoscopic retrograde cholangiopancreatography devices    59
5.2.2.2    Development of other procedures like EUS and MRCP    60
5.2.2.3    Shortage of trained physicians and endoscopists    60
5.2.3    MARKET OPPORTUNITIES    60
5.2.3.1    The growing healthcare sector in emerging economies    60
5.2.3.2    Increasing adoption of single-use endoscopy instruments    61
5.2.4    MARKET CHALLENGES    61
5.2.4.1    Product recalls witnessed by major market players    61
TABLE 3    LIST OF PRODUCT RECALLS    61
5.2.4.2    Side-effects and infections (like post-ERCP pancreatitis) caused by duodenoscopy products    62
6    INDUSTRY INSIGHTS    63
6.1    INTRODUCTION    63
6.2    TECHNOLOGY TRENDS    63
6.2.1    ARTIFICIAL INTELLIGENCE IN GI ENDOSCOPY    63
TABLE 4    AI SYSTEMS AND OTHER RELATED FUNCTIONS    63
6.2.2    SINGLE-USE ENDOSCOPES    64
TABLE 5    ADVANTAGES OF DISPOSABLE OR SINGLE-USE ENDOSCOPES OVER REUSABLE ENDOSCOPES    64
6.2.3    ROBOT-ASSISTED ENDOSCOPES    65
TABLE 6    ROBOT-ASSISTED ENDOSCOPY PRODUCTS    66
6.3    INDUSTRY TRENDS    66
6.3.1    FAVOURABLE REIMBURSEMENT SCENARIO FOR SINGLE-USE DEVICES    66
6.4    PRICING ANALYSIS    66
TABLE 7    AVERAGE SELLING PRICE OF FLEXIBLE HD AND NON-HD DUODENOSCOPE (USD)    66
TABLE 8    US: AVERAGE COST OF ERCP PROCEDURES, 2020 (USD)    67
6.5    VALUE CHAIN ANALYSIS    68
FIGURE 25    VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE    68
6.6    ECOSYSTEM MAPPING    69
FIGURE 26    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: ECOSYSTEM ANALYSIS    69
6.7    SUPPLY CHAIN ANALYSIS    70
FIGURE 27    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: STAKEHOLDERS IN SUPPLY CHAIN    71
6.8    PORTER’S FIVE FORCES ANALYSIS    71
TABLE 9    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: PORTER’S FIVE FORCES ANALYSIS    71
6.8.1    THREAT OF NEW ENTRANTS    72
6.8.1.1    High capital requirement    72
6.8.1.2    High preference for products from well-established brands    72
6.8.2    THREAT OF SUBSTITUTES    72
6.8.2.1    Substitute therapies for ERCP procedures    72
6.8.3    BARGAINING POWER OF SUPPLIERS    72
6.8.3.1    Presence of several raw material suppliers    72
6.8.3.2    Supplier switching costs    72
6.8.4    BARGAINING POWER OF BUYERS    72
6.8.4.1    Few companies offer premium products at the global level    72
6.8.5    INTENSITY OF COMPETITIVE RIVALRY    73
6.8.5.1    Increasing demand for high-quality and innovative products    73
6.8.5.2    Lucrative growth potential in emerging markets    73
6.9    REGULATORY ANALYSIS    73
6.10    PATENT ANALYSIS    74
6.10.1    PATENT PUBLICATION TRENDS FOR ERCP    74
FIGURE 28    GLOBAL PATENT PUBLICATION TRENDS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, 2017–2021    74
6.10.2    TOP APPLICANTS (COMPANIES) OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS    75
FIGURE 29    TOP COMPANIES THAT APPLIED FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021    75
6.10.3    JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET    75
FIGURE 30    JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021    75
6.11    TRADE ANALYSIS    76
TABLE 10    NUMBER OF EXPORTS AND IMPORTS RELATED TO ERCP EQUIPMENT    76
6.12    IMPACT OF COVID-19 ON THE ENDOSCOPY EQUIPMENT MARKET    77
7    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT    78
7.1    INTRODUCTION    79
TABLE 11    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    79
7.2    ENDOSCOPES    79
7.2.1    THE RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES IS EXPECTED TO DRIVE THE ENDOSCOPES MARKET    79
TABLE 12    ENDOSCOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    80
7.3    ENDOTHERAPY DEVICES    81
7.3.1    THESE ARE MINIMALLY INVASIVE DEVICES USED TO TREAT OR DIAGNOSE GI CONDITIONS    81
TABLE 13    ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)    81
TABLE 14    ENDOTHERAPY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    82
7.3.2    SPHINCTEROTOME    82
7.3.2.1    The risk of bleeding post-sphincterotomy is 2%, with 0.1% mortality    82
TABLE 15    SPHINCTEROTOME MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    83
7.3.3    LITHOTRIPTER    83
7.3.3.1    Lithotripters are used to pulverize stones into smaller pieces so that they can pass out of a body naturally    83
TABLE 16    LITHOTRIPTER MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    84
7.3.4    STENTS    84
7.3.4.1    Metal stents have higher patency rates and are less expensive than plastic stents    84
TABLE 17    STENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    85
7.3.5    CANNULAS    85
7.3.5.1    The success rate of ERCP procedures is directly proportional to cannulation    85
TABLE 18    CANNULAS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    86
7.3.6    FORCEPS    86
7.3.6.1    The prevalence of cancer leads to significant demand for biopsy forceps for the collection of tissue samples    86
TABLE 19    FORCEPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    87
7.3.7    SNARES    87
7.3.7.1    Snares are commonly used for cold or hot polypectomy    87
TABLE 20    SNARES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    88
7.3.8    CATHETERS    88
7.3.8.1    Catheters inject a contrast medium for the visualization of internal tissues    88
TABLE 21    CATHETERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    89
7.3.9    GUIDING WIRES    89
7.3.9.1    The most used guidewires in ERCP come in three different diameters: 0.018, 0.025, and 0.035 inches    89
TABLE 22    GUIDING WIRES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    90
7.3.10    BALLOONS    90
7.3.10.1    Balloon endoscopy involves balloons that inflate and deflate to pinch together the walls of the GI tract    90
TABLE 23    BALLOONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    91
7.3.11    BASKETS    91
7.3.11.1    Baskets are commonly used instruments for the removal of bile duct stones in ERCP    91
TABLE 24    BASKETS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    92
7.4    VISUALIZATION SYSTEMS    92
7.4.1    VISUALIZATIONS SYSTEMS HAVE APPLICATIONS ACROSS ALL ERCP PROCEDURES    92
TABLE 25    VISUALIZATION SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    93
7.5    ENERGY DEVICES    93
7.5.1    ENERGY DEVICES CAN BE MONOPOLAR OR BIPOLAR    93
TABLE 26    ENERGY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    94
7.6    OTHERS    94
TABLE 27    ERCP ACCESSORIES AND DESCRIPTIONS    94
TABLE 28    OTHERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    95
8    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE    96
8.1    INTRODUCTION    97
TABLE 29    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)    97
8.2    BILIARY SPHINCTEROTOMY    97
8.2.1    INCREASING INCIDENCE RATES OF SOD TO DRIVE THE GROWTH OF THIS SEGMENT    97
TABLE 30    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION)    98
8.3    BILIARY DILATATION    98
8.3.1    HIGH-CHOLESTEROL DIETS AND OBESITY ARE THE KEY CAUSES OF GALLSTONES, THUS DRIVING THE UPTAKE OF BILIARY DILATATION PROCEDURES    98
TABLE 31    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY DILATATION, BY COUNTRY, 2019–2026 (USD MILLION)    99
8.4    BILIARY STENTING    99
8.4.1    THE RISING PREVALENCE OF GALLBLADDER DISEASES IN THE GROWING GERIATRIC POPULATION IS EXPECTED TO PROPEL THE DEMAND FOR BILIARY STENTS    99
TABLE 32    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY STENTING, BY COUNTRY, 2019–2026 (USD MILLION)    100
8.5    PANCREATIC SPHINCTEROTOMY    100
8.5.1    THE RISING INCIDENCE OF PANCREATIC CANCER IS EXPECTED TO DRIVE THE DEMAND FOR THIS PROCEDURE    100
TABLE 33    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION)    101
8.6    PANCREATIC DUCT DILATATION    101
8.6.1    BALLOON DILATION ALONG WITH ENDOSCOPIC SPHINCTEROTOMY IS THE PREFERRED PROCEDURE FOR STONE REMOVAL    101
TABLE 34    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC DUCT DILATATION, BY COUNTRY, 2019–2026 (USD MILLION)    102
8.7    PANCREATIC DUCT STENTING    102
8.7.1    PANCREATIC DUCT STENTING IS THE TREATMENT OF CHOICE FOR CHRONIC PANCREATIC DISORDERS    102
TABLE 35    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC DUCT STENTING, BY COUNTRY, 2019–2026 (USD MILLION)    103
9    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER    104
9.1    INTRODUCTION    105
TABLE 36    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    105
9.2    HOSPITALS    105
9.2.1    INCREASING INVESTMENTS BY GOVERNMENT ORGANISATIONS BOOST THE ADOPTION OF ERCP BY THIS END-USER SEGMENT    105
TABLE 37    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION)    106
9.3    AMBULATORY SURGERY CENTERS/CLINICS    106
9.3.1    AMBULATORY SURGERY CENTERS PROVIDE OUTPATIENT ECRP PROCEDURES THROUGH EFFICIENT OPERATIONS    106
TABLE 38    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)    107
9.4    OTHER END USERS    107
TABLE 39    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)    108
10    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION    109
10.1    INTRODUCTION    110
FIGURE 31    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES    110
TABLE 40    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION, 2019–2026 (USD MILLION)    111
10.2    NORTH AMERICA    111
FIGURE 32    NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT    112
TABLE 41    NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    112
TABLE 42    NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    113
TABLE 43    NORTH AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    113
TABLE 44    NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION)    114
TABLE 45    NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER,
 2019–2026 (USD MILLION)    114
10.2.1    US    114
10.2.1.1    The large market in the US is mainly driven by high healthcare spending in the country and the increasing incidence of cancer    114
TABLE 46    MEDICARE NATIONAL AVERAGE COVERAGE FOR OUTPATIENT PROCEDURES, 2020    115
TABLE 47    LIST OF DEVICES THAT RECEIVED FDA APPROVALS BETWEEN 2018 AND 2021    116
TABLE 48    US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    116
TABLE 49    US: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)    117
TABLE 50    US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    117
TABLE 51    US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    118
10.2.2    CANADA    118
10.2.2.1    High costs of endoscopic retrograde cholangiopancreatography to restrain the market growth in Canada    118
TABLE 52    INCIDENCE ESTIMATES BY CANCER TYPE (CANADA)    118
TABLE 53    CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    119
TABLE 54    CANADA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    120
TABLE 55    CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    120
TABLE 56    CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY END USER, 2019–2026 (USD MILLION)    121
10.3    EUROPE    121
TABLE 57    EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY COUNTRY, 2019–2026 (USD MILLION)    121
TABLE 58    EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    122
TABLE 59    EUROPE: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    122
TABLE 60    EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    123
TABLE 61    EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY END USER, 2019–2026 (USD MILLION)    123
10.3.1    GERMANY    123
10.3.1.1    Germany’s rising geriatric population is one of the key drivers for the ERCP market    123
TABLE 62    GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    124
TABLE 63    GERMANY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)    125
TABLE 64    GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    125
TABLE 65    GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY END USER, 2019–2026 (USD MILLION)    126
10.3.2    UK    126
10.3.2.1    Investments by hospitals to purchase new & advanced ERCP equipment is expected to propel market growth in the UK    126
TABLE 66    UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    127
TABLE 67    UK: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)    127
TABLE 68    UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    128
TABLE 69    UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    128
10.3.3    FRANCE    128
10.3.3.1    High healthcare expenditure is expected to support the growth of the ERCP market in France    128
TABLE 70    FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    129
TABLE 71    FRANCE: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    129
TABLE 72    FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    130
TABLE 73    FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    130
10.3.4    SPAIN    130
10.3.4.1    Increasing prevalence of cardiovascular diseases in Spain to stimulate the market growth for endoscopes    130
TABLE 74    SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    131
TABLE 75    SPAIN: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    131
TABLE 76    SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    132
TABLE 77    SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    132
10.3.5    ITALY    132
10.3.5.1    Rising government initiatives for the adoption of advanced medical equipment to drive the market growth for ERCP equipment & procedures in Italy    132
TABLE 78    ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    133
TABLE 79    ITALY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)    133
TABLE 80    ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    134
TABLE 81    ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    134
10.3.6    REST OF EUROPE (ROE)    134
TABLE 82    ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    135
TABLE 83    ROE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)    135
TABLE 84    ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    136
TABLE 85    ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    136
10.4    ASIA PACIFIC    136
FIGURE 33    ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT    137
TABLE 86    ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY COUNTRY, 2019–2026 (USD MILLION)    138
TABLE 87    ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    138
TABLE 88    ASIA PACIFIC: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    139
TABLE 89    ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    139
TABLE 90    ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY END USER, 2019–2026 (USD MILLION)    140
10.4.1    JAPAN    140
10.4.1.1    Supportive medical device reimbursement policies to drive the market growth for ERCP in Japan    140
TABLE 91    JAPAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    141
TABLE 92    JAPAN: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    141
TABLE 93    JAPAN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    142
TABLE 94    JAPAN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    142
10.4.2    CHINA    142
10.4.2.1    Large patient population and the strong need for healthcare infrastructure improvements to drive the market growth in China    142
TABLE 95    CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    143
TABLE 96    CHINA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    143
TABLE 97    CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    144
TABLE 98    CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    144
10.4.3    INDIA    144
10.4.3.1    Favorable government initiatives for improvements in healthcare infrastructure to support the market growth for ERCP in India    144
TABLE 99    INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    145
TABLE 100    INDIA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    145
TABLE 101    INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    146
TABLE 102    INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    146
10.4.4    AUSTRALIA    146
10.4.4.1    The high number of cancer rates in Australia is expected to drive the demand for endoscopy instruments    146
TABLE 103    AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    147
TABLE 104    AUSTRALIA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
 2019–2026 (USD MILLION)    147
TABLE 105    AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    148
TABLE 106    AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY END USER, 2019–2026 (USD MILLION)    148
10.4.5    REST OF ASIA PACIFIC (ROAPAC)    148
TABLE 107    ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    149
TABLE 108    ROAPAC: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    149
TABLE 109    ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    150
TABLE 110    ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    150
10.5    LATIN AMERICA    150
10.5.1    THE GOVERNMENTS IN MANY LATIN AMERICAN COUNTRIES ARE FOCUSED ON IMPROVING HEALTHCARE INFRASTRUCTURE, AND IN TURN, THE ADOPTION OF ERCP IS EXPECTED TO RISE    150
TABLE 111    LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    151
TABLE 112    LATIN AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    152
TABLE 113    LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION)    152
TABLE 114    LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER,
2019–2026 (USD MILLION)    153
10.5.2    MIDDLE EAST    153
10.5.2.1    Healthcare infrastructural advancements are expected to create the requirement for advanced hospital equipment such as ERCP in the region    153
TABLE 115    MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    153
TABLE 116    MIDDLE EAST: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)    154
TABLE 117    MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    154
TABLE 118    MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY END USER, 2019–2026 (USD MILLION)    155
10.5.3    AFRICA    155
10.5.3.1    High prevalence of target diseases and initiatives to strengthen endoscopic services in healthcare organizations to propel market growth    155
TABLE 119    AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PRODUCT, 2019–2026 (USD MILLION)    156
TABLE 120    AFRICA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
 2019–2026 (USD MILLION)    156
TABLE 121    AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET,  BY PROCEDURE, 2019–2026 (USD MILLION)    157
TABLE 122    AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)    157
11    COMPETITIVE LANDSCAPE    158
11.1    OVERVIEW    158
11.2    KEY PLAYER STRATEGIES/RIGHT-TO-WIN    158
11.2.1    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET    158
11.3    REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS    160
FIGURE 34    REVENUE ANALYSIS OF KEY PLAYERS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET    160
11.4    COMPETITIVE BENCHMARKING    161
TABLE 123    FOOTPRINT OF COMPANIES IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET    161
TABLE 124    PRODUCT AND SERVICE: COMPANY FOOTPRINT (25 COMPANIES)    162
TABLE 125    END USER: COMPANY FOOTPRINT (25 COMPANIES)    163
TABLE 126    REGION: COMPANY FOOTPRINT (26 COMPANIES)    164
11.5    COMPETITIVE LEADERSHIP MAPPING    165
11.5.1    STAR    165
11.5.2    EMERGING LEADER    165
11.5.3    PERVASIVE PLAYER    166
11.5.4    PARTICIPANT    166
FIGURE 35    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)    166
11.6    COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES    167
11.6.1    PROGRESSIVE COMPANY    167
11.6.2    DYNAMIC COMPANY    167
11.6.3    STARTING BLOCK    167
11.6.4    RESPONSIVE COMPANY    167
FIGURE 36    ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES (2020)    168
11.7    MARKET RANKING ANALYSIS    168
FIGURE 37    ERCP MARKET RANKING ANALYSIS, BY PLAYER, 2020    169
FIGURE 38    ENDOTHERAPY DEVICES MARKET RANKING ANALYSIS, BY PLAYER, 2020    170
11.8    COMPETITIVE SCENARIO    170
TABLE 127    PRODUCT LAUNCHES & APPROVALS, 2019–2021    170
TABLE 128    DEALS, 2019–2021    171
12    COMPANY PROFILES    173
(Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made)*
12.1    KEY PLAYERS    173
12.1.1    OLYMPUS CORPORATION    173
TABLE 129    OLYMPUS CORPORATION: BUSINESS OVERVIEW    173
FIGURE 39    COMPANY SNAPSHOT: OLYMPUS CORPORATION (2020)    174
12.1.2    CONMED CORPORATION    178
TABLE 130    CONMED CORPORATION: BUSINESS OVERVIEW    178
FIGURE 40    COMPANY SNAPSHOT: CONMED CORPORATION (2020)    179
12.1.3    AMBU A/S    181
TABLE 131    AMBU A/S: BUSINESS OVERVIEW    181
FIGURE 41    COMPANY SNAPSHOT: AMBU A/S (2020)    182
12.1.4    BOSTON SCIENTIFIC CORPORATION    184
TABLE 132    BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW    184
FIGURE 42    COMPANY SNAPSHOT: BOSTON SCIENTIFIC CORPORATION (2020)    185
12.1.5    JOHNSON & JOHNSON    189
TABLE 133    JOHNSON & JOHNSON: BUSINESS OVERVIEW    189
FIGURE 43    COMPANY SNAPSHOT: JOHNSON & JOHNSON (2020)    190
12.1.6    FUJIFILM HOLDINGS CORPORATION    193
TABLE 134    FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW    193
FIGURE 44    COMPANY SNAPSHOT: FUJIFILM HOLDINGS CORPORATION (2020)    194
12.1.7    MEDTRONIC, PLC    197
TABLE 135    MEDTRONIC, PLC: BUSINESS OVERVIEW    197
FIGURE 45    COMPANY SNAPSHOT: MEDTRONIC, PLC (2020)    198
12.1.8    KARL STORZ SE & CO. KG    201
TABLE 136    KARL STORZ SE & CO. KG.: BUSINESS OVERVIEW    201
12.1.9    COOK MEDICAL    204
TABLE 137    COOK MEDICAL: BUSINESS OVERVIEW    204
12.1.10    HOYA CORPORATION    206
TABLE 138    HOYA CORPORATION: BUSINESS OVERVIEW    206
FIGURE 46    COMPANY SNAPSHOT: HOYA CORPORATION (2020)    207
12.1.11    B. BRAUN MELSUNGEN AG    209
TABLE 139    B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW    209
FIGURE 47    COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG (2020)    210
12.1.12    HOBBS MEDICAL, INC.    212
TABLE 140    HOBBS MEDICAL, INC.: BUSINESS OVERVIEW    212
12.1.13    STERIS PLC    213
FIGURE 48    COMPANY SNAPSHOT: STERIS PLC (2020)    213
TABLE 141    STERIS PLC: BUSINESS OVERVIEW    214
12.1.14    MERIT MEDICAL SYSTEMS, INC.    216
TABLE 142    MERIT MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW    216
FIGURE 49    COMPANY SNAPSHOT: MERIT MEDICAL SYSTEMS, INC. (2020)    217
12.1.15    TELEMED SYSTEMS, INC.    219
TABLE 143    TELEMED SYSTEMS, INC.: BUSINESS OVERVIEW    219
12.1.16    CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.    220
TABLE 144    CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW    220
12.1.17    MEDI-GLOBE GMBH    222
TABLE 145    MEDI-GLOBE GMBH: BUSINESS OVERVIEW    222
12.1.18    TAEWOONG MEDICAL CO., LTD.    223
TABLE 146    TAEWOONG MEDICAL CO., LTD.: BUSINESS OVERVIEW    223
12.1.19    HUGER MEDICAL INSTRUMENT CO., LTD.    224
TABLE 147    HUGER MEDICAL INSTRUMENT CO., LTD..: BUSINESS OVERVIEW    224
12.1.20    INTROMEDIC CO., LTD.    225
TABLE 148    INTROMEDIC CO., LTD.: BUSINESS OVERVIEW    225
FIGURE 50    COMPANY SNAPSHOT: INTROMEDIC CO., LTD. (2020)    225
12.1.21    SONOSCAPE MEDICAL CORP.    227
TABLE 149    SONOSCAPE MEDICAL CORP.: BUSINESS OVERVIEW    227
FIGURE 51    COMPANY SNAPSHOT: SONOSCAPE MEDICAL CORP (2020)    227
12.2    OTHER PLAYERS    228
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made might not be captured in case of unlisted companies.
13    APPENDIX    230
13.1    DISCUSSION GUIDE    230
13.2    KNOWLEDGE STORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL    234
13.3    AVAILABLE CUSTOMIZATIONS    236
13.4    RELATED REPORTS    236
13.5    AUTHOR DETAILS    237"